| Retrospective Non-interventional Study of Stiripentol Use in Dravet Patients in the USA (NCT05544058) | Biocodex | 2022-04-27 |
| Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies (NCT05364021) | Longboard Pharmaceuticals | 2022-03-03 |
| Applicability and Effectiveness of Remote Occupational Therapy (NCT07592650) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2021-12-16 |
| Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution (NCT05044819) | Jazz Pharmaceuticals | 2021-07-07 |
| An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome (NCT04740476) | Stoke Therapeutics, Inc | 2021-01-20 |
| Natural History Study of Infants and Children With Developmental and Epileptic Encephalopathies (NCT04537832) | Encoded Therapeutics | 2021-01-18 |
| Transcranial Magnetic Stimulation to Measure Cortical Excitability in Dravet Syndrome (NCT04614506) | Boston Children's Hospital | 2020-11-02 |
| A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome (NCT04462770) | Epygenix | 2020-09-15 |
| An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome (NCT04442295) | Stoke Therapeutics, Inc | 2020-06-29 |
| Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syndrome (NCT04611438) | Yonsei University | 2020-03-30 |
| Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects. (NCT04069689) | Epygenix | 2019-08-29 |
| A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome (NCT03936777) | Zogenix, Inc. | 2019-04-22 |
| Early Check: Expanded Screening in Newborns (NCT03655223) | RTI International | 2018-10-15 |
| A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies (NCT03650452) | Takeda | 2018-08-08 |
| Turmeric as Treatment in Epilepsy (NCT03254680) | NYU Langone Health | 2018-03-01 |
| A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol (NCT03467113) | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | 2018-01-19 |
| Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome (NCT02318563) | INSYS Therapeutics Inc | 2017-12-30 |
| A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome (NCT03299842) | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | 2017-07-12 |
| The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy (NCT02815540) | Gillette Children's Specialty Healthcare | 2017-02-16 |
| A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome (NCT02926898) | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | 2017-01-27 |
| Treatment of Gait Disorders in Children With Dravet Syndrome (NCT03857451) | Universiteit Antwerpen | 2017-01-01 |
| The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy (NCT02910297) | Gillette Children's Specialty Healthcare | 2016-09-01 |
| An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome (NCT02823145) | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | 2016-06-08 |
| A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome (NCT02682927) | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | 2016-01-15 |
| Neuronal Excitability of HCN1 Channel Mutations in Dravet Syndrome (NCT02896608) | Fondation Ophtalmologique Adolphe de Rothschild | 2015-10-29 |
| An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes (NCT02224573) | GW Research Ltd | 2015-06-11 |
| GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome (NCT02224703) | Jazz Pharmaceuticals | 2015-04-13 |
| Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1) (NCT02091375) | Jazz Pharmaceuticals | 2015-03-30 |
| Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome (NCT02174094) | H. Lundbeck A/S | 2015-03-01 |
| A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1) (NCT02091206) | Jazz Pharmaceuticals | 2014-10-22 |
| Genetic Analysis Between Charlotte's Web Responders Versus Non- Responders in a Dravet Population (NCT02229032) | University of Colorado, Denver | 2014-08-01 |
| Stiripentol in Dravet Syndrome (NCT01533506) | Mayo Clinic | 2012-02-01 |
| ZX008 Expanded Access Protocol (NCT03780127) | Zogenix, Inc. | |
| Expanded Access Use of Stiripentol in Dravet Syndrome or Sodium Channel Mutation Epileptic Encephalopathies (NCT02239276) | Cook Children's Health Care System | |
| Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome (NCT01983722) | Children's Hospital Medical Center, Cincinnati | |
| Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol) (NCT04437004) | University of California, Los Angeles | |
| Compassionate Use of Stiripentol in Dravet Syndrome (NCT01835314) | University of Colorado, Denver | |